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Background: Cervical cancer (CC) and genital warts (GW) are a significant public health issue in Venezuela. Our
objective was to assess the cost-effectiveness of the two available vaccines, bivalent and quadrivalent, against
Human Papillomavirus (HPV) in Venezuelan girls in order to inform decision-makers.
Methods: A previously published Markov cohort model, informed by the best available evidence, was adapted to
the Venezuelan context to evaluate the effects of vaccination on health and healthcare costs from the perspective
of the healthcare payer in an 11-year-old girls cohort of 264,489. Costs and quality-adjusted life years (QALYs) were
discounted at 5%. Eight scenarios were analyzed to depict the cost-effectiveness under alternative vaccine prices,
exchange rates and dosing schemes. Deterministic and probabilistic sensitivity analyses were performed.
Results: Compared to screening only, the bivalent and quadrivalent vaccines were cost-saving in all scenarios,
avoiding 2,310 and 2,143 deaths, 4,781 and 4,431 CCs up to 18,459 GW for the quadrivalent vaccine and gaining
4,486 and 4,395 discounted QALYs respectively. For both vaccines, the main determinants of variations in the
incremental costs-effectiveness ratio after running deterministic and probabilistic sensitivity analyses were
transition probabilities, vaccine and cancer-treatment costs and HPV 16 and 18 distribution in CC cases. When
comparing vaccines, none of them was consistently more cost-effective than the other. In sensitivity analyses,
for these comparisons, the main determinants were GW incidence, the level of cross-protection and, for some
scenarios, vaccines costs.
Conclusions: Immunization with the bivalent or quadrivalent HPV vaccines showed to be cost-saving or cost-
effective in Venezuela, falling below the threshold of one Gross Domestic Product (GDP) per capita (104,404 VEF)
per QALY gained. Deterministic and probabilistic sensitivity analyses confirmed the robustness of these results.
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Cervical cancer (CC) is the fourth most common cancer
in women worldwide with an estimated toll of 528,000
new cases and 266,000 deaths in 2012 [1]. In Latin
America and the Caribbean region (LAC) the age-
standardized incidence rates ranged from 14.6 to 44.0
per 100,000 women per year, values probably underesti-
mated due to insufficient coverage and frequency of
screening, inadequate collection and analysis of cyto-
logical samplings as well as incomplete follow-up of
cases [2, 3]. The Bolivarian Republic of Venezuela is a
South-American country with a population of 27.2
million people where 1 in 3 women is aged 15 years and
older and are at risk of developing CC [4]. In this country,
CC is the first most common female cancer in women
aged 15 to 44 years, accounting for 1,973 new cases diag-
nosed in 2011 and 1,789 new CC-related deaths annually
for all ages [5, 6].
The Human Papillomavirus (HPV) infection occurs
commonly in sexually active women; it has been identi-
fied as the necessary cause of CC and has been associ-
ated with other types of cancer [7–9]. High-risk types of
HPV (HPV 16, 18, 45, 31, 33, 39, 52, 58 and 35) have
been recognized as a necessary etiological agent for the
development of CC and premalignant cervical lesions,
being detected in up to 99.7% of such cases [10–13].
Low-risk HPV types (6, 11, 34, 40, 42, 43 and 44) have
been associated with genital warts (GW) and low-grade
cervical lesions. Among Venezuelan women, HPV types
16 and 18 were identified as the most common high-risk
HPV types with an overall prevalence of 80% in patients
with CC [14, 15]. It is established that CC comprehen-
sive prevention approaches, including well-organized
cervical screening programs using Papanicolaou smear
tests (Pap), can reduce CC incidence and mortality [16].
Additionally, the introduction of HPV vaccination is ex-
pected to also reduce the burden of CC [17]. Currently,
there are two available vaccines: a bivalent vaccine tar-
geting high-risk HPV 16 and 18 (Cervarix™, GSK) and
quadrivalent vaccine targeting, in addition to the above,
also low-risk HPV 6 and 11 types (Gardasil, Merck)
[18]. Both vaccines have proven efficacy in the preven-
tion of lesions associated with the HPV types they target
[19, 20].. Currently in Venezuela, there is a nationwide
CC screening program including Paps for women of 25
to 65 years old. However, the HPV vaccine has not yet
been incorporated into the national vaccination program
and consequently, there is no vaccination coverage [5, 21].
Cost-effectiveness analysis is a useful tool to assist de-
cision makers in assessing the value of specific interven-
tions and inform resource-allocation decisions. Several
models based on economic evaluations have been con-
ducted to assess the cost-effectiveness of interventions
that reduce HPV-associated premalignant and malignantlesions in Latin America, including vaccination [22, 23].
The results of the analyses vary widely from country to
country due to differences in epidemiological factors
such as the incidence of certain HPV-related diseases,
local treatment patterns and related costs [22]. Therefore,
a country-specific assessment needs to be conducted in
order to suitably inform local decision-makers.
The aim of the present study was to perform an eco-
nomic evaluation based on a cohort model adapted to
estimate the lifetime cost and clinical outcomes of vac-
cination with the bivalent and quadrivalent vaccination
schemes, comparing them with the current policy in
Venezuela of no vaccination.
Methods
Model structure
A previously published lifetime Markov cohort model
with a 1-year cycle was adapted to reflect the Venezue-
lan setting. The model simulated the natural history of
oncogenic HPV in CC, the effect of screening and the
impact of vaccination over the lifetime of the cohort.
[24–26] The current model has been extended to in-
clude infection with low-risk HPV types (HPV 6 and
HPV 11) that might progress to cervical intraepithelial
neoplasia grade 1 (CIN1) and/or to GW (Fig. 1) [18, 27].
The perspective was stated as of the healthcare payer in-
cluding direct medical costs only. The analysis allowed
the estimation of costs and effects of each of the three
intervention strategies: current screening program,
current screening program in addition to vaccination
with the bivalent vaccine, and current screening program
in addition to vaccination with the quadrivalent vaccine.
For this analysis, a lifetime horizon was adopted. In order
to reflect the range of possible results taking into account
different vaccine costs, alternative exchange rates for
Venezuela, and 2-dose schedule vs. 3-dose schedule, eight
scenarios were considered for the base-case analyses, as
detailed in the following sections.
Input parameters
An extensive review of the literature was done in MED-
LINE and LILACS. Local information related to epi-
demiology, use of resources and costs associated to
HPV-lesions treatment was collected. Priority to local
sources of information was given. Selected parameters
were used to populate the model and were reviewed
and validated by experts. Input parameters included are
summarized in Table 1.
Vaccinated population and coverage
Based on demographic data from the National Institute
of Statistics of Venezuela, the model included a cohort
of girls aged 11 years (n = 264,489) [4]. Vaccination
coverage was assumed to reach 95% for a 3 dose scheme
Fig. 1 Model structure. Abbreviations: GCM+: Gardasil-Cervarix Model; CIN1onc, cervical intraepithelial neoplasia 1 oncogenic; CIN1lr, low-risk cervical
intraepithelial neoplasia 1; det, CIN health state detected through screening: same pathways as CIN nondetected CIN health state but with different
probabilities; HPV, human papillomavirus; HPVlr, low-risk HPV infection; HPVonc, oncogenic HPV infection; NoHPVonc, no oncogenic HPV infection,
CIN2/3, cervical intraepithelial neoplasia 2 or 3
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nomic evaluation using the same model in Chile and the
coverage observed for other vaccines in the country [28].
Epidemiological data
The general mortality rate by age in Venezuelan women
was calculated from overall deaths and distribution of
female population in 2011 [4, 6]. Number of deaths,
overall mortality rate and mortality rate stratified by age
were obtained from the National Mortality Yearbook of
the Ministry of Health of Venezuela [6]. The age-specific
incidence of high- and low-risk HPV was calculated
based on data from a Venezuelan study [29] and ad-
justed to an age-specific tendency shown in a Chilean
population-based study [30]. Data for GW incidence
were scarce in the region; thus, the age-specific inci-
dence of GW was matched to data reported in a large
German population-based cohort study [31], in which
the incidence is in average what is reported for many
countries [32]. Data on type-specific distribution of HPV
in CIN1, CIN2/3 and CC were obtained from Correnti
et al. [14] and Sanchez-Lander et al. [15] Distribution of
HPV 6 and 11 in GW was obtained from Avila et al.
[33] Data on CIN1 and CIN2/3 natural history were
obtained from Petry [34]. Information on treatment out-
comes was provided by Melnikow et al. [35] and by local
experts. Five-year CC cure rate for Venezuela was set on
41.5%, according to Rodriguez et al. [36] The coverage
of regular screening of Pap was reported to be 35% every
3 years from age 25 to 64 years old [21, 37] and thepercentage of positive Pap per screening campaign was
5% based on local experts opinion. Pap-smear-test-
operative characteristics for CIN1 and CIN2/3 were
obtained from Colantonio et al. [22]
Treatment costs
The model requires cost data for five health events’
treatments: screening, CIN1, CIN2/3, genital warts and
cancer. In all cases we estimated expected costs using a
micro-costing approach, which required to identify the
resources used, the intensity of use and their unit costs.
The list of resources were obtained from local literature
[38] and their expected use was estimated using annual
utilization rates obtained from administrative databases
of Dr. Luis Razetti Oncologic Institute from Caracas,
Venezuela, and validated through an expert opinion. All
unit costs are of 2015 and were obtained from five local
private health facilities, two of them of primary health
care where 85% of the population with private coverage
usually attend, while three with a high complexity level.
Public tariffs were approximated from the last available
Gaceta Oficial [39] and a private ambulatory health
facility similar in costs. Finally, tariffs were weighted ac-
cording to the distribution of utilization of public (74%)
and private (26%) institutions [40]. When necessary
costs were adjusted using the national Consumer Price
Index [41] Details about unit costs, expected quantities
and expected costs, treatment costs, vaccination costs
per scenario and total costs (micro-costing) can be
found in the Additional file 1.
Table 1 Input data values: base-case values, associated ranges, probabilities distributions assumed and sources
Inputs Value (range) Source
Population data
11-years old women cohort 264,489 - [4]
Transition probabilities
HPV onc regression 0.50 (0.23; 0.77) Uniform (0.23; 0.77) [18, 64]
HPV onc to CIN1 progression 0.05 (0.03; 0.07) Normal (0.03; 0.07) [18, 64]
CIN1 onc regression 0.36 (0.22; 0.78) Normal (0.22; 0.78) [18, 64]
CIN1 onc to CIN2/3 progression 0.14 (0.08; 0.16) Normal (0.08; 0.16) [18, 64]
CIN2/3 regression to no HPV 0.25 (0.23; 0.32) Normal (0.23; 0.32) [18, 64]
CIN2/3 progression to cancer 0.14 (0.10; 0.15) Normal (0.10; 0.15) [18, 64]
HPV low-risk CIN1 0.04 (0.03; 0.05) Normal (0.03; 0.05) [18, 64]
Genital wart resistance 0.35 (0.28; 0.42) Uniform (0.28; 0.42) [65]
Proportion CIN1 onc detected and treated 0.30 (0.24; 0.36) Uniform (0.24; 0.36) Exp. Op
CIN1 treatment success 0.94 (0.75; 1.00) Uniform (0.75; 1.00) [35]
Proportion CIN2/3 detected and treated 0.90 (0.72; 1.00) Uniform (0.72; 1.00) Exp. Op
CIN2/3 treatment success 0.88 (0.70; 1.00) Uniform (0.70; 1.00) [35]
Utility weights
No HPV 1.000 - [18]
HPV 1.000 - [18]
Genital Wart 0.02 (0.02; 0.02) Uniform (0.02; 0.02) [18]
CIN1 1.000 - [18]
CIN1 detected 0.01 (0.01; 0.02) Uniform (0.01; 0.02) [18]
CIN2/3 1.000 - [18]
CIN2/3 detected 0.01 (0.01; 0.01) Uniform (0.01; 0.01) [18]
Cancer 0.27 (0.22; 0.33) Uniform (0.22; 0.33) [18]
Cancer cured 0.06 (0.05; 0.07) Uniform (0.05; 0.07) [18]
Death 0.000 - [18]
Screening Characteristics
Regular screening coverage 35% - [21]
Interval between regular screening 3 years (& scenario of 5y) - [37]
Irregular screening coverage 25% - Exp. Op
Population without screening 40% - Exp. Op
Age of initiation of screening 25 years - [21]
Sensitivity to detect CIN1 0.58 (0.38; 0.56) Normal (0.38; 0.56) [22]
Sensitivity to detect CIN2 and CIN3 0.61 (0.69; 0.87) Normal (0.69; 0.87) [22]
Estimated positive Pap smear 0.05 (0.05; 0.06) Uniform (0.04; 0.06) Exp. Op
Parameters to estimate vaccine effectiveness
Prevalence of HPV types 16 and 18 in cervical cancer 0.80 (0.64; 0.96) Uniform (0.64; 0.96) [15]
Prevalence of other oncogenic HPV in cervical cancer 0.16 (0.13; 0.19) Uniform (0.13; 0.19) [15]
Prevalence of HPV types 16 and 18 in CIN2/3 0.55 (0.44; 0.66) Uniform (0.44; 0.66) [14]
Prevalence of other oncogenic HPV in CIN2/3 0.34 (0.27; 0.41) Uniform (0.27; 0.41) [14]
Prevalence of HPV types 16 and 18 in CIN1 0.27 (0.21; 0.32) Uniform (0.21; 0.32) [14]
Prevalence of other oncogenic HPV in CIN1 0.28 (0.22; 0.33) Uniform (0.22; 0.33) [14]
Prevalence of HPV types 6 and 11 in CIN1 0.14 (0.11; 0.17) Uniform (0.11; 0.17) [14]
Prevalence of HPV types 6 and 11 in GW 0.95 (0.76; 1.00) Uniform (0.76; 1.00) [33]
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Table 1 Input data values: base-case values, associated ranges, probabilities distributions assumed and sources (Continued)
Vaccine efficacy to HPV types 16 and 18 CC (Bivalent) 0.98 (0.94; 1.00) Normal (0.94; 1.00) [43, 44]
Vaccine efficacy to HPV types 16 and 18 CC (Quadrivalent) 0.98 (0.94; 1.00) Normal (0.94; 1.00) [45]
Vaccine efficacy to HPV types 16 and 18 CIN2/3 (Bivalent) 0.98 (0.97; 0.99) Normal (0.97; 0.99) [43, 44]
Vaccine efficacy to HPV types 16 and 18 CIN2/3 (Quadrivalent) 0.98 (0.97; 0.99) Normal (0.97; 0.99) [45]
Vaccine efficacy to HPV types16 and 18 CIN1 (Bivalent) 0.98 (0.97; 0.99) Normal (0.97; 0.99) [43, 44]
Vaccine efficacy to HPV types16 and 18 CIN1 (Quadrivalent) 0.98 (0.97; 0.99) Normal (0.97; 0.99) [45]
Vaccine efficacy to other oncogenic HPV CC (Bivalent) 0.68 (0.68; 0.68) Normal (0.68; 0.68) [47–50]
Vaccine efficacy to other oncogenic HPV CC (Quadrivalent) 0.33 (0.33; 0.33) Normal (0.33; 0.33) [46]
Vaccine efficacy to other oncogenic HPV CIN2/3 (Bivalent) 0.68 (0.68; 0.68) Normal (0.68; 0.68) [47–50]
Vaccine efficacy to other oncogenic HPV CIN2/3 (Quadrivalent) 0.33 (0.33; 0.33) Normal (0.33; 0.33) [46]
Vaccine efficacy to other oncogenic HPV CIN1 (Bivalent) 0.48 (0.48; 0.48) Normal (0.48; 0.48) [47–50]
Vaccine efficacy to other oncogenic HPV CIN1 (Quadrivalent) 0.23 (0.23; 0.23) Normal (0.23; 0.23) [46]
Vaccine efficacy to HPV types 6 and 11 (Quadrivalent) 0.98 (0.94; 1.00) Normal (0.94; 1.00) [66, 67]
GW incidence (10-79 years) 0.17% (0.089; 0.245) Truncated Normal (Mean; range) [31]
Costs
Regular screening (Bs.F) $2,943 (2,207; 3,678) Uniform (2,207; 3,678) see costs section
CIN1Onc newly detected (Bs.F) $20,749 (15,562; 25,936) Uniform (15,562; 25,936)
CIN2/3 newly detected (Bs.F) $22,230 (16,672; 27,787) Uniform (16,672; 27,787)
CIN1Onc det (Bs.F) $15,284 (11,463; 19,105) Uniform (11,463; 19,105)
CIN2/3 det (Bs.F) $28,355 (21,266; 35,444) Uniform (21,266; 35,444)
Cancer (Bs.F) $273,788 (205,341; 342,234) Uniform (205,341; 342,234)
Genital Wart (Bs.F) $9,568 (7,176; 11,960) Uniform (7,176; 11,960)
Vaccine bivalent (per dose) (USD) $ 8.5 -
Vaccine quadrivalent (per dose) USD; Scenarios 1-4 $ 8.5 -
Vaccine quadrivalent (per dose) USD; Scenerios 5-8 $ 13.8 -
Abbreviations: NIS National Institute of Statistics, MoH Ministry of Health, VEF Venezuelan bolívar fuerte, US$ United States dollar, Exp. Op expert opinion, BV bivalent,
QV quadrivalent, CIN cervical intraepithelial neoplasia, CC cervical cancer, HPV human papillomavirus, VE vaccine efficacy, GW genital wart, y year
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Vaccine prices per person were calculated as the unit price
of vaccines multiplied by the number of doses. Delivery
costs were assumed to be equal for both vaccines and
therefore were not considered in the analysis. Because
there was uncertainty at the time the study was done
about the price that Venezuela would pay once the vac-
cines were incorporated into the national program, two of
the scenarios were projected considering equal price per
dose at US$ 8.5 for each vaccine. The other scenario con-
sidered differential prices: US$ 8.5 per dose of the bivalent
vaccine and US$ 13.79 per dose of the quadrivalent
vaccine. These prices are based on last available Pan
American Health Organization (PAHO) price agreements
and projections for both vaccines, that is for 2013 [42].
Exchange rates
A key issue in the analysis is the election of the exchange
rate. While expressing all values in USD or in VEF does
not change results, the election of the rate does it be-
cause vaccines prices comes in USD and all the othercosts are local estimations expressed in VEF. At the mo-
ment the analysis was done, there were in Venezuela
several prevailing exchange rates and considering that it
is not clear which one truly represents the opportunitiy
costs of trading currencies, we decided to represent this
uncertainty creating two scenarios for the most relevant
rates: the exchange rate of 6.3 VEF per US$ (agreement
No. 14, Ministry of Health of Venezuela vaccines pur-
chase exchange rate) and the exchange rate of 170 VEF
per US$ (agreement No. 33, regular citizens purchase
exchange rate). Hence, choosing one rate over the other
makes costs vary 27 times. Vaccine prices obtained from
the PAHO Revolving Fund in US$.
Vaccine efficacy and cross-protection
For the estimation of vaccine effectiveness, HPV type-
specific vaccine efficacy for both vaccines was considered
as 98% against CC, CIN1 and CIN2/3 associated with
HPV 16 and 18 with a lifelong duration [43–45]. The com-
bined efficacy of the ten most frequent oncogenic HPV
non-vaccine types (31,33,35,39,45,51,52,56,58 and 59) was
Bardach et al. BMC Public Health  (2017) 17:152 Page 6 of 15considered jointly. Vaccine efficacy for these types, for the
quadrivalent vaccine was 23.4% (95% Confident Interval –
CI : 7.8-36.4) and 32.5% (95% CI: 6.0-51.9) for CIN1 and
CIN2+, respectively [46]. Vaccine efficacy for the bivalent
vaccine for these ten non-vaccine oncogenic types was
47.7% (95% CI 28.9 to 61.9) and 68.4 (95% CI: 45.7 to
82.4) for CIN1 and CIN2+, respectively [47–50]. Consider-
ing the latest evidence regarding the efficacy of the 2-dose
scheme, case scenarios comparing the 2-dose schedule vs.
the currently approved 3-dose schedule were developed;
the same level and duration of efficacy and cross-
protection were considered for both regimes [51–58]. In
all scenarios, the duration of cross-protection for the
base-case was set at 10 years, with a 5-year waning period.
Scenarios considered
For Venezuela, we needed to consider eight different
plausible base-case scenarios, defined by the combination
of a) two different official exchange rates, b) two number
of doses per scheme, and c) two differential prices of
vaccines (Table 2).
Outcomes
The present exercise explored health outcomes and
disease-related costs for the different scenarios considered;
we considered life years (LYs), QALYs, number of cervical
cancer cases and deaths, number of new and recurrent
genital warts, and total costs other than vaccination,
including costs of screening, of CIN cases, warts and
cancer cases. Another set of outcomes explored was the
vaccine costs per scenario.
Discounting
The health benefits and costs were discounted at an an-
nual rate of 5.0% based on guidelines recommendations
for economic evaluations in LAC [59]. The effect of this
discount rate on the outcomes was assessed in the dif-
ferent scenarios.Table 2 Summary of base-case scenarios
Scenario Vaccine
Price in USD
Exchange rate Dose scheme
1 BV: 8.5 - QV: 8.5 6.3 3 doses
2 BV: 8.5 - QV: 8.5 6.3 2 doses
3 BV: 8.5 - QV: 8.5 170 3 doses
4 BV: 8.5 - QV: 8.5 170 2 doses
5 BV: 8.5 - QV: 13.79 6.3 3 doses
6 BV: 8.5 - QV: 13.79 6.3 2 doses
7 BV: 8.5 - QV: 13.79 170 3 doses
8 BV: 8.5 - QV: 13.79 170 2 doses
For all these scenarios, the same cross protection and screening interval
was assumed
Abbreviations: BV bivalent, QV quadrivalent, VEF Venezuelan bolívar fuerte,
US$ United States dollarCalibration
The model was calibrated by modifying input parameters
to match the model output to the data from vital statistics
of Venezuela, keeping transition probabilities within pre-
determined ranges of plausibility (Fig. 2). Age-specific CC
incidence and mortality rates, as well as the overall
number of cases and deaths estimated by the model were
matched to observed vital statistics’data. On average,
modeled event rates were within +/-10% of the observed
event rates. Age-specific CC incidence and mortality were
graphed and the resulting estimated and observed curves
were visually explored to confirm a good fit. Since up-to-
date cancer incidence data are likely to reflect a worse
screening coverage prevailing in the past, the model was
also calibrated using coverage rates representative of the
Venezuelan situation 15 years ago, according to the con-
sensus opinion of the group of authors.
Deterministic and probabilistic sensitivity analysis
Parameter uncertainty was represented with one-way
and multi-way sensitivity analyses. The objective in the
first case was to identify the main drivers of results. Each
parameter was varied separately from its base-case value
according to a specific range (Table 1) which for all
parameters were defined following three strategies ac-
cording to the availability of information: i) using the
reported confidence intervals when possible ii) approxi-
mating them using the percentage of variations re-
ported in other studies [22, 60] iii) approximating them
based on expert opinions.. The analysis was performed
for the eight scenarios and summarized in tornado dia-
grams for costs and QALYs separately. Since the con-
struction of the eight scenarios affects only costs, we
included one tornado diagram for QALYs. (see Appendix)
The probabilistic exercise was performed for each scenario
to quantify the effect of uncertainty surrounding the
model input parameters and to calculate probabilities of
being cost-effective. In every case 1,000 simulations were
generated to produce a distribution of the model results
(Table 1) and was performed comparing both bivalent
and quadrivalent vaccines vs. screening alone and bi-
valent vs. quadrivalent vaccines schemes. Simulations
were plotted on the cost-effectiveness plane and used to
construct cost-effectiveness acceptability curves (CEAC).
These curves depict the probability of being the cost-
effective option of the three (to have a higher monetary
benefit) [61] for each intervention according to different
units of GDP per capita as threshold values. The values
the curves show can be interpreted as the probabilities
of being the preferred option at different cost-
effectiveness thresholds [62]. Only scenarios 2 and 4
(same vaccine price with 2-dose schemes) were pre-
sented for sensitivity analyses, and the rest can be
found in the additional online material.
Fig. 2 Model calibration. Observed vs. model predicted values. Incidence (a) and mortality (b) of invasive cervical cancer in Venezuela predicted
by the model and observed by Globocan and National Health Statistics
Bardach et al. BMC Public Health  (2017) 17:152 Page 7 of 15Results
Calibration
The model was calibrated to properly reflect the epidemi-
ology of Venezuela. The model predicted rates of CC inci-
dence and deaths closely matched to the incidence data
for invasive CC reported by Globocan 2012 [63] and the
mortality data for invasive CC reported by the National
Mortality Yearbook of the Ministry of Health of Venezuela
[6], as shown in Fig. 2. The difference between the
observed and the modeled cumulative CC cases and
deaths was below 10%.
For the cohort of 264,489 girls, the most important
health outcomes and disease-related costs, discounted
and undiscounted, are depicted in Table 3-A. These re-
sults show the differential gains between bivalent vaccine
vs. no vaccination, quadrivalent vaccine vs. no vaccin-
ation and both vaccines against each other. Also, these
results do not differ between scenarios, as their differences
are mainly due to vaccine-related costs and exchange rates
used for the different scenarios. Independently of the type
of vaccine considered, there are gains in QALYs, life-years
(LYs), CC cases and prevented deaths as compared to
no vaccination, both considering discounted and undis-
counted results. When comparing both vaccines against
each other, the bivalent vaccine gains 3,544 undiscounted
additional QALYs vs. the quadrivalent vaccine. Also, there
are fewer CC cases and related deaths with the bivalent
vaccine than with the quadrivalent for both undiscounted
and discounted results. Regarding GWs, the quadrivalent
prevented 18,469 new and recurrent GW cases (not
discounted). Excluding the costs of vaccination, total
medical costs for bivalent vaccine are slightly higher in
the discounted scenario and lower in the undiscounted,
when compared to the quadrivalent vaccine. The overall
cost of the different vaccination programs for each sce-
nario are presented in Table 3-B for the 2-dose schemescenarios (2, 4) and in Additional file 1: Table S2 for the
3-dose scheme scenarios (1, 3, 5 and 7) and 2-dose
scheme scenario with differential pricing for vaccines.
Discounted results for incremental QALYs, costs and
cost-effectiveness ratios between bivalent and quadrivalent
vs. no vaccination strategies and vaccines against each
other (considering different scenarios for the vaccine
costs) are summarized in Table 4 and Additional file 1:
Table S3. Whatever vaccine-cost scenario is considered,
any vaccination strategy is cost-saving or cost-effective
compared with the status quo (no vaccination) using a 1
GDP per capita threshold. When comparing the bivalent
vs. the quadrivalent vaccines, ICERs showed that there
were small differences between them for the first six
scenarios; however, when different prices per dose are
considered, under and at an exchange rate equal to
170 VEF per US$, the bivalent strategy is dominant
(Scenarios 7 and 8).
Deterministic sensitivity analyses
Tornado graphs for QALYs differences (Fig. 3) resulted
in similar shapes for bivalent and quadrivalent vaccin-
ation strategies when compared to no vaccination. Dis-
count rate was the main determinant due to differential
horizon of costs and benefits, followed by transition
probabilities. When comparing bivalent vs. quadrivalent
strategies, the differences in QALYs (x-axis) were lower.
Once again, the discount rate was the main determinant
of variation. Cross-protection was the second parameter
in importance and had a symmetrical and inverse impact
over incremental QALY; that is, when no cross-protection
was assumed, difference in QALY became lower and
more negative, but when we considered a lifetime cross-
protection, the impact was not so relevant in magnitude.
These variations in assumptions do not change the con-
clusion that vaccines are cost-effective vs. screening alone.








QV - NV BV - NV BV-QV
A: Health outcomes and disease-related costs
Undiscounted
LYs 18,351,285 18,395,244 18,398,735 43,959 47,451 3,491
QALYs 18,337,584 18,390,430 18,393,973 52,845 56,389 3,544
Cervical cancer cases 7,398 2,967 2,616 −4,431 −4,781 −350
Cervical cancer deaths 3,701 1,558 1,391 −2,143 −2,310 −168
Genital Warts (new and recurrent) 21,025 2,566 21,025 −18,459 0 18,459
Total cost other than vaccinationa 11,295.9 VEF 7,109.9 VEF 7,107.3 VEF −4,186.0 VEF −4,188.6 VEF −2.6 VEF
Costs of screening 4,323.0 VEF 4,396.1 VEF 4,383.3 VEF 73.1 VEF 60.3 VEF −12.8 VEF
Costs of CIN 1 601.4 VEF 303.3 VEF 344.9 VEF −298.1 VEF −256.5 VEF 41.5 VEF
Costs of CIN 2/3 262.3 VEF 122.7 VEF 102.6 VEF −139.6 VEF −159.7 VEF −20.1 VEF
Costs of warts 309.2 VEF 37.7 VEF 309.3 VEF −271.4 VEF 0.1 VEF 271.6 VEF
Costs of cancer 5,800.1 VEF 2,250.1 VEF 1,967.3 VEF −3,550.0 VEF −3,832.7 VEF −282.7 VEF
Discounted (5%)
LYs 5,277,952 5,281,034 5,281,282 3,082 3,330 248
QALYs 5,276,066 5,280,461 5,280,552 4,395 4,486 91
Total cost other than vaccinationa 2,435.2 VEF 1,602.7 VEF 1,672.5 VEF −832.6 VEF −762.8 VEF 69.8 VEF
Costs of screening 1,130.3 VEF 1,151.9 VEF 1,148.5 VEF 21.6 VEF 18.2 VEF −3.5 VEF
Costs of CIN 1 167.1 VEF 82.8 VEF 91.8 VEF −84.3 VEF −75.4 VEF 9.0 VEF
Costs of CIN 2/3 79.5 VEF 35.2 VEF 28.6 VEF −44.3 VEF −50.9 VEF −6.6 VEF
Costs of warts 136.7 VEF 16.7 VEF 136.7 VEF −120.0 VEF 0.0 VEF 120.0 VEF
Costs of cancer 921.6 VEF 316.0 VEF 266.9 VEF −605.6 VEF −654.7 VEF −49.1 VEF
B: Vaccine costs per scenarioa
2: Both vaccines = 8.5 US$; 2-dose scheme - FX 6.3 0 VEF 26.9 VEF 26.9 VEF 26.9 VEF 26.9 VEF 0 VEF
4: Both vaccines = 8.5 US$; 2-dose scheme - FX: 170 0 VEF 726.2 VEF 726.2 VEF 726.2 VEF 726.2 VEF 0 VEF
6: BV: 8.5 US$ QV: 13.79 US$; 2-dose scheme - FX 6.3 0 VEF 43.7 VEF 26.9 VEF 43.7 VEF 26.9 VEF −16.7 VEF
8: BV: 8.5 US$ QV: 13.79 US$; 2-dose scheme - FX: 170 0 VEF 1,178.1 VEF 726.2 VEF 1,178.1 VEF 726.2 VEF −451.9 VEF
Notes: A. Health outcomes and disease related costs (with and without discounting); B. Cost of vaccination (Scenarios 2, 4, 6 and 8)
Abbreviations: NV no vaccination, QV quadrivalent, BV bivalent, FX foreign exchange rate (VEF per US$), CC cervical cancer. (See scenarios 1, 3, 5, 7 in
Additional file 1: Table S2), VEF Venezuelan bolívar fuerte, QALYs quality-adjusted life years, LYs life-years, CIN cervical intraepithelial neoplasia, US$ United States dollar
aCosts are expressed in millions of VEF, 2015
Table 4 Total QALYs, total costs, and incremental cost-effectiveness ratios for scenarios 2, 4, 6 and 8a
Scenario Quadrivalent vs No vaccination Bivalent vs No vaccination Bivalent vs Quadrivalent
ΔQALYs ΔCOSTS ICER ΔQALYs ΔCOSTS ICER ΔQALYs ΔCOSTS ICER
Scenario
2: Both vaccines = 8.5 US$;
2-dose scheme - FX 6.3
4,395 −805.7 US$ cost-saving 4,486 −735.9 VEF cost- saving 91 69.8 VEF 0.77
4: Both vaccines = 8.5 US$;
2-dose scheme - FX: 170
−106.4 US$ cost- saving −36.6 VEF cost- saving 69.8 VEF 0.77
6: BV: 8.5 US$ QV: 13.79 US$;
2-dose scheme - FX 6.3
−788.9 US$ cost- saving −735.9 VEF cost- saving 53.0 VEF 0.58
8: BV: 8.5 US$ QV: 13.79 US$;
2-dose scheme - FX: 170
345.5 US$ 0.08 −36.6 VEF cost-saving −382.1 VEF cost-saving
Notes: Results for a cohort of 264,489 women (discount = 5%)
Abbreviations: FX exchange rate (VEF per US$), QV quadrivalent, BV bivalent. GDP per capita: 104,404 VEF. [68] (See scenarios 1, 3, 5, 7 in Additional file 1: Table S2),
QALYs quality-adjusted life years, ICER incremental cost-effectiveness ratio, VEF Venezuelan bolívar fuerte, US$ United States dollar
aCosts and ICERs are expressed in millions of VEF, 2015
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Fig. 3 Deterministic Sensitivity Analysis: Tornado graph for QALYs
differences. Discount rate = 5%. Abbreviations: T_pob: HPVlr_NoHPV =
transition probability to regress from low risk HPV to no HPV;
Scenario_Crossprotection = refers to the presence of lifetime cross-
protection or no cross-protection at all; T_prob: HPVOnc_NoHPV =
Transition probability to regress from infection with oncogenic
HPV to no HPV; T_prob: HPVOnc_CIN1 = Transition probability to
progress from infection with oncogenic HPV to CIN1; T_prob:
CIN1Onc_CIN2/3 = Transition probability to progress from infection
with oncogenic HPV and CIN1 to CIN2/3; T_prob: CIN2/3_Cancer =
Transition probability to progress from CIN2/3 to cancer; T_prob:
CIN1Onc_cured = Transition probability to cure from oncogenic HPV
infection with CIN1; T_prob: CIN2/3_Cured = Transition probability
to cure from CIN2/3; T_prob: Cancer_Cured = Transition probability
to cure from cervical cancer; Vac_efficacy_1618_Cervarix = Vaccine
efficacy for oncogenic types with quadrivalent vaccine; Vac_efficacy_
1618_Gardasil = Vaccine efficacy for oncogenic types with bivalent
vaccine; Vac_eff_other_Gardasil = Vaccine efficacy for non-vaccine
oncogenic HPV types with bivalent vaccine; Perc_HPV_6_11 = Proportion
of HPV 6 and 11 in genital warts; Perc_other_CC = Proportion of
non-vaccine oncogenic HPV types among Cervical Cancer; Perc_HP-
VOnc = Proportion of HPV 16 and 18 among Cervical Cancer; QALYs:
quality-adjusted life years; HPV: Human Papillomavirus
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analysis (scenarios 2 and 4) are presented in Fig. 4 and
3-dose scheme analysis (scenarios 1, 3, 5 and 7) and sce-
narios with different vaccine prices with 2-dose scheme
can be found in the Additional file 1. No parameter can
modify the cost-saving results when any vaccine is com-
pared with no vaccination in scenarios 2 and 6. There
are several parameters than can modify the cost-saving
result when any vaccine is compared with no vaccination
in scenario 4 or when the bivalent vaccine is compared
with no vaccination in scenario 8 (the most significant
ones are the discount rate and the transition probabil-
ities). Finally, only the discount rate can modify the
result that the quadrivalent vaccine requires a positive
investment in order to generate a cost-saving result (as
shown for the bivalent vaccine) in scenario 8. The
sensitivity analysis between vaccines showed that no
parameter could modify the result that the quadrivalent
vaccine was more costly than the bivalent vaccine in
scenarios 2 and 6. The costs of both vaccines are the
only parameters that can modify the result that the
quadrivalent vaccine is more costly than the bivalent
vaccine in scenario 4. Finally, no parameter can modify
the result that the bivalent vaccine is less costly than
the quadrivalent vaccine in scenario 8.
Probabilistic sensitivity analyses
Cost-effectiveness plane and CEACs for interventions
are presented in Fig. 5 for the scenarios 2 and 4. The
other scenarios can be found in the Additional file 1. In
each scenario, a first scatter-plot graph shows the results
for both vaccines vs. no vaccination, and a second one
shows the comparison of the vaccines against each other,
Fig. 4 (See legend on next page.)
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Fig. 4 Deterministic sensitivity analysis – a) Scenario 2 Tornado graph for costs differences in scenario 2 (same vaccine price per dose of 8.5 US$,
exchange rate of 6.3 VEF, scheme of 2 doses) b) Scenario 4 Tornado graph for costs differences in scenario 4 (same vaccine price per dose of 8.5
US$, exchange rate of 170 VEF, scheme of 2 doses). Discount rate = 5%. Abbreviations: COSTS_Genital Wart = Costs of genital warts management;
COSTS_Cancer = Costs of cervical cancer management; COSTS_Vaccine cervarix = Cost of quadrivalent vaccine; COST_Vaccine Gardasil = Cost
of bivalent vaccine; Scenario_Crossprotection = refers to the presence of lifetime cross-protection or no cross-protection at all; T_pob: HPVlr_
NoHPV = transition probability to regress from low-risk HPV to no HPV; T_prob: HPVOnc_NoHPV = Transition probability to regress from infection
with oncogenic HPV to no HPV; T_prob: HPVOnc_CIN1 = Transition probability to progress from infection with oncogenic HPV to CIN1; T_prob:
CIN1Onc_CIN2/3 = Transition probability to progress from infection with oncogenic HPV and CIN1 to CIN2/3; T_prob: CIN2/3_Cancer = Transition
probability to progress from CIN2/3 to cancer; T_prob: CIN1Onc_cured = Transition probability to cure from oncogenic HPV infection with CIN1;
T_prob: CIN2/3_Cured = Transition probability to cure from CIN2/3; T_prob: Cancer_Cured = Transition probability to cure from cervical cancer;
Vac_efficacy_1618_Cervarix = Vaccine efficacy for oncogenic types with quadrivalent vaccine; Vac_efficacy_1618_Gardasil = Vaccine efficacy for
oncogenic types with bivalent vaccine; Vac_eff_other_Gardasil = Vaccine efficacy for non-vaccine oncogenic HPV types with bivalent vaccine;
Perc_HPV_6_11 = Proportion of HPV 6 and 11 in genital warts; Perc_other_CC = Proportion of non-vaccine oncogenic HPV types among Cervical
Cancer; Perc_HPVOnc = Proportion of HPV 16 and 18 among Cervical Cancer; HPV: Human Papillomavirus; VEF: Venezuelan bolívar fuerte; US$:
United States dollar
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cines are cost-saving or cost-effective vs. no vaccination
considering one GDP per capita (104,404 VEF), regard-
less of the discount applied (data not shown). Both the
scatter-plots and the acceptability curves reflect the un-
certainty from the three main variables that shape the
different scenarios (i.e., exchange rates, number of doses
and vaccine costs) and no superiority was detected of
one vaccine over the other in scenarios 2, 4 and 6. In the
scenarios considering a differential vaccine cost and an
exchange rate of 170 VEF per US$ (scenario 8), the bi-
valent vaccine has 64% probabilities of being dominant
and 100% probabilities of being cost-saving compared to
the quadrivalent vaccine. The results are very sensitive
to the discount rate (data not shown).
Acceptability curves for the studied scenarios indicate
the probability that the intervention is cost-effective
when compared to the alternatives, according to different
thresholds or monetary values of QALYs expressed as
units of GDP per capita. In all cases, the curves support
the results suggested by the scatter plots. When compar-
ing both vaccination interventions to screening only, all
scenarios show that vaccines options are a cost-effective
choice; however, in the comparison between vaccines, the
analysis becomes diffuse. In one hand, the scenarios 2, 4
and 6 show the quadrivalent vaccine as the option with
the higher probabilities of being the most cost-effective
choice, with a threshold of at least 1 GDP per capita. The
last scenario (scenario 8) on the other hand, shows the
bivalent vaccine as having the highest probability of being
the most cost-effective intervention. These results suggest,
therefore, that the probability of being the most cost-
effective intervention deeply depends on the scenario se-
lected for analysis of exchange rate and vaccine prices.
Discussion
Our study assessed the cost-effectiveness of HPV vac-
cination of 11-year-old girls in Venezuela vs. status quo
(current screening strategy), from the healthcare systemperspective, through adapting to this country a cohort
model that has been used previously in other nations
[18, 28]. Both vaccines currently available against HPV,
the bivalent and the quadrivalent, were evaluated. The
model was calibrated to reflect local HPV epidemiology
in Venezuela.
Similarly to other studies, we faced difficulties to
examine this issue in terms of the significant uncer-
tainty of many model parameters, such as intervention,
outcome costs, local epidemiological information and
vaccine efficacy. Moreover, many countries are adopting a
2-dose scheme, even though the evidence is not as strong
as for the 3-dose schedule.
Due to the current economic context in Venezuela,
additional hurdles were to obtain adequate currency ex-
change rates to use (since the impact of the international
price of the vaccine may vary greatly), as well as com-
parative vaccine prices. Though recent official prices
showed that the bivalent vaccine was less costly, we
considered an equal price per dose as well. So, instead
of reporting a single base-case analysis, as it is usually
the case in economic evaluations, and in order to in-
corporate these ranges of possible results, we needed to
consider eight base-case scenarios including different
exchange rates, different and equal vaccine prices and
2- and 3-dose schemes.
As a limitation of the model, vaccine delivery costs
were not considered. However these costs do not alter
results when comparing vacines, and in the scenarios
versus no vaccination, the diferences observed in cost
per QALY-gained are so important that the effect of
including them would be within the range of what is
considered cost-effective.
It is worthy to highlight that although the model was
calibrated adequately with the epidemiologic value
ranges reported by the Ministry of Health, the lack of
accurate national information on some key parameters
made us frequently use estimates from international
literature and expert validation, similarly to previous
Fig. 5 (See legend on next page.)
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Fig. 5 Probabilistic sensitivity analysis – Scatter plots for a) costs and b) QALYs differences, c) Cost-effectiveness acceptability curves (probability
of being the most cost-effective intervention) for scenario 2 (same vaccine price per dose of 8.5 US$, exchange rate of 6.3 VEF, scheme of 2 doses) and
scenario 4 (same vaccine price per dose of 8.5 US$, exchange rate of 170 VEF, scheme of 2 doses). Discount rate = 5%. Abbreviations: VEF: Venezuelan
bolívar fuerte; US$: United States dollar; GDP: Gross Domestic Product
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in 11-year-old girls in Venezuela would significantly
reduce HPV-related diseases, and that they would be ei-
ther cost-saving or cost-effective in all scenarios. Both
the bivalent and quadrivalent vaccines showed similar
results against no vaccination.
On six scenarios assessed, avoided costs were greater
than costs of vaccination, resulting in cost-saving strat-
egies. In two scenarios only – those using higher exchange
rates and differential vaccines costs-vaccination was more
costly than current screening. Nevertheless, in both cases,
both vaccines were cost-effective, with costs per QALYs of
less than 1 GDP per capita.
While the bivalent vaccine reduced a larger number of
CC cases and deaths as compared with the quadrivalent
vaccine, the quadrivalent reduced also the number of
GWs. The net effect was a slight difference in LYs and
QALYs in favor of the bivalent vaccine, though these re-
sults were highly dependent on the assumptions of the
study, especially in cross-protection and incidence of GW.
It was clear and consistent that any vaccination strat-
egy for HPV prevention would not only be beneficial
for the health of women in Venezuela, but it would also
be cost-saving or cost-effective, and thus a good inter-
vention from the public health point of view. There was
uncertainty regarding the relative cost-effectiveness of
both vaccines. Accordingly, it is difficult to draw con-
clusions on the comparative performance of the differ-
ent vaccines since the results are less clear and had
significant heterogeneity in the tested scenarios: in
some scenarios the bivalent vaccine was cost-saving or
cost-effective compared to the quadrivalent, while in
others it was clearly not.
Conclusions
Despite uncertainty in Venezuela concerning costs data,
exchange rates and epidemiological parameters, the
main conclusion of the present study is that HPV vac-
cination provides significant health benefits, being ei-
ther a cost-saving or a cost-effective strategy against the
current practice of screening and no vaccination.
Given the uncertainties identified and because of the
relatively similar overall benefit of both vaccines mea-
sured in LYs or QALYs, the decision of choosing one
vaccine over another should take into consideration not
only the cost-effectiveness, but also other aspects that
differentiate both vaccines that can be valued in the
local context.Additional file
Additional file 1: Presents the tornado graphs for deterministic
sensitivity analyses and scatter plots for costs and QALYs/cost-effectiveness
acceptability curves for probabilistic sensitivity analyses for scenarios 1, 3, 5
and 7 (3-dose schemes), and scenarios 2 and 4 (2-dose schemes). Also
presents micro-costing details. (DOCX 698 kb)
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